Wedbush Reaffirms “Outperform” Rating for Bicara Therapeutics (NASDAQ:BCAX)

Wedbush restated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report sent to investors on Thursday morning,RTT News reports. They currently have a $31.00 target price on the stock.

BCAX has been the topic of several other reports. HC Wainwright increased their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $13.40 on Thursday. The stock has a fifty day moving average of $13.04. Bicara Therapeutics has a 52-week low of $11.10 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, sell-side analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of BCAX. The Manufacturers Life Insurance Company purchased a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $582,000. FMR LLC purchased a new position in Bicara Therapeutics in the third quarter valued at about $57,913,000. Walleye Capital LLC bought a new position in Bicara Therapeutics in the third quarter worth about $809,000. Vestal Point Capital LP purchased a new stake in shares of Bicara Therapeutics during the third quarter valued at about $10,825,000. Finally, Braidwell LP bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.